¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦7ȸ Æó°íÇ÷¾Ð ¿¬·Ê Çмú´ëȸ(PH Korea 2022) : 2022-11-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦7ȸ Æó°íÇ÷¾Ð ¿¬·Ê Çмú´ëȸ(PH Korea 2022) : 2022-11-19
±³À°ÀÏÀÚ : 2022-11-19
±³À°Àå¼Ò : ¼ÛµµÄÁº¥½Ã¾Æ  
±³À°ÁÖÁ¦ : ´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦7ȸ Æó°íÇ÷¾Ð ¿¬·Ê Çмú´ëȸ(PH Korea 2022)
ÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : Çö°æ¸²
¿¬¶ôó : 032-460-3663  
À̸ÞÀÏ : kphs.or@gmail.com      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ÀÎõ±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 10,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 09:00~09:15 Pulmonary hypertension classification case: CTD-PAH(Group 1)  ¹éÀç¼÷(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 09:15~09:30 Pulmonary hypertension classification case: LHD-PH: IpcPH, CpcPH, and LVAD-PH(Group 2)  À念¿ì(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 09:30~09:45 Pulmonary hypertension classification case: ILD-PH(Group 3)  ÀåÇ×Á¦(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 09:45~10:00 Pulmonary hypertension classification case:CTEPH(Group 4)  ¾Èö¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 10:00~10:15 Pulmonary hypertension classification case:Misc. Multifactorial-PH(Group 5)  ÀÌÁÖÈñ(ÃæºÏÀÇ´ë) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 10:15~10:35 Pulmonary hypertension classification case based learning  ±è´ëÈñ(¿ï»êÀÇ´ë) 
È޽Ġ11-19 ÇÁ¸®¹Ì¾îº¼·ë 10:35~10:55 È޽Ġ () 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 10:55~11:25 ESC-ERS 2022 Guideline  Stephan Rosencranz(University of Cologne, Germany) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 11:25~11:40 Lessons 2020 Korean PH guideline  ¹ÚÀçÇü(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 11:40~11:55 Proposals for next Korean PH guideline  ÃÖÁ¤Çö(ºÎ»êÀÇ´ë) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 11:55~12:10 How to make New Korean PH Guideline?  ³ªÁø¿À(°í·ÁÀÇ´ë) 
½Ä»ç 11-19 ÇÁ¸®¹Ì¾îº¼·ë 12:10~13:10 ½Ä»ç  () 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 13:10~13:25 Update of PH incidence in Korea  ÀüÂùÈ«(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 13:25~13:40 Update of insurance system for PH drugs in Korea  Çϱâ¼ö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 13:40~13:55 How to use new drug and devices for PH in Korea  ±è±â¹ü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 13:55~14:10 Government support for PH treatment in Japan  Hiromi Matsubara(Okayama University Graduate School of Medicine, Japan) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 14:10~14:25 Policy session for pulmonary hypertension treatment  ±è°èÈÆ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 14:25~14:40 South Korea_Muldisciplinary Approach for Better Outcome  ¾È°æÁø(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 14:40~14:55 Japan_Muldisciplinary Approach for Better Outcome  Yu Taniguchi(Kobe University) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 14:55~15:10 China_Muldisciplinary Approach for Better Outcome  Yu-Ping Zhou(Peking Union Medical College Hospital) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 15:10~15:25 Taiwan (Genetic study for pulmonary arterial hypertension-central Taiwan study)  Kae-woei Liang(China Medical University Hospital, Taiwan) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 15:25~15:40 EASOPH session: Muldisciplinary Approach for Better Outcome  Á¤ÁßÈ­(Á¶¼±ÀÇ´ë) 
È޽Ġ11-19 ÇÁ¸®¹Ì¾îº¼·ë 15:40~16:00 È޽Ġ () 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 16:00~16:15 Pediatric PH in Japan today  Shouzaburoh Doi(Tokyo Medical and Dental University, Japan) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 16:15~16:30 Biomarkers for PH diagnosis and grading  ÀÌÀç½Â(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 16:30~16:45 Devices for G2 PH  ÃÖÁø¿À(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 16:45~17:00 New trials for PH treatment  ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø) 
±³À°½Ã°£ 11-19 ÇÁ¸®¹Ì¾îº¼·ë 17:15~17:30 Intensive PAH treatment  Hiromi Matsubara(Okayama Univ., Japan) 
Åä·Ð 11-19 ÇÁ¸®¹Ì¾îº¼·ë 17:30~17:45 Update for pulmonary hypertension management  ±èÁöÈñ(°¡Å縯ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦7ȸ Æó°íÇ÷¾Ð ¿¬·Ê Çмú´ëȸ(PH Korea 2022) : 2022-11-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ Ãß°èÇмú´ëȸ : 2022-11-19
´ÙÀ½±Û ¿ï»ê±¤¿ª½ÃÀÇ»çȸ ¸¸¼ºÁúȯÀÇ ÃÖ½ÅÁö°ß : 2022-11-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 810 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 825 2018-08-15
420 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦1ȸ ºñ¸¸Àü¹®°¡ ½ÉÈ­°úÁ¤: ºñ¸¸ Àü¹® ÀÎÁ¤ÀÇ ±³À° Part 1. : 2018-09-09 0 584 2018-08-15
419 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø 2018³â Çù·Âº´ÀÇ¿ø ÀÇ»ç ¿¬¼ö°­Á : 2018-09-09 0 1,366 2018-08-15
418 ¼­¿ï Á¦1ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ESD¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-08 0 876 2018-08-15
417 ¼­¿ï Á¦11ȸ ¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø ÁßȯÀÚÀÇÇÐ ¿¬¼ö°­Á Basic Concepts in Intensive Care, 2018 (BACIC 2018) : 2018-09-08 0 1,384 2018-08-15
416 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ °í·Á´ëÇб³ °í°üÀý ½ÉÆ÷Áö¿ò : 2018-09-08 0 1,108 2018-08-15
415 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-08 0 522 2018-08-15
414 ºÎ»ê ´ëÇѼ¼Æ÷º´¸®ÇÐȸ International Session of the 30th Annual Fall Meeting of the Korean Society for Cytopathology : 2018-09-08 0 601 2018-08-15
413 ºÎ»ê 2018³â ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ ´ç´¢º´±³À°ÀÚ ¼¼¹Ì³ª : 2018-09-08 0 1,092 2018-08-15
412 ±¤ÁÖ Àü³²´ëº´¿ø Á¦ 3Â÷ Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç ¿¬¼ö°­Á : 2018-09-08 0 1,092 2018-08-15
411 ºÎ»ê ºÎ»ê´ëº´¿ø 2018³â Á¦1Â÷ ¸ð¹ß¿¬¼ö±³À° (ÁÖÁ¦: Å»¸ðÁõÀÇ Áø´Ü°ú Ä¡·á) : 2018-09-08 0 1,437 2018-08-15
410 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¦6ȸ ¾ÆÁÖ ´ç´¢¹ß ¹× â»ó ½ÉÆ÷Áö¾ö : 2018-09-08 0 1,217 2018-08-15
409 ±¤ÁÖ 2018 Àü³²´ëÇб³º´¿ø ÁßȯÀÚÀÇÇнÉÆ÷Áö¿ò ¹× ±â°èȯ±â¿öÅ©¼ó : 2018-09-08 0 742 2018-08-15
408 ¼­¿ï 2018 ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥ : 2018-09-07 0 469 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷